DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.

The surge is attributed to the company's outstanding financial results, which showed annual total revenue skyrocketing 133.7% year-on-year to RMB 164 million. A key driver was the technology licensing business, whose revenue exploded by 331.7% to RMB 84.34 million, becoming the company's largest income source for the first time with a gross profit margin nearing 87.3%.

This dramatic growth in its core licensing segment is seen as a powerful validation of the commercial closed-loop for its medical AI large model. The endorsement of its iMedImage® foundational model by leading institutions further solidifies its strategic position as a global AI medical infrastructure service provider, fueling investor confidence.